Writer: dr. Ria Oktavia

Depok, November 24th 2025 – The Bioavailability and Bioequivalence (BA/BE) Center of PT Biometrik Riset Indonesia welcomed an audit by the Indonesian Food and Drug Authority (BPOM) as part of the regulatory assessment to ensure compliance with national standards for BA/BE study implementation.

The audit team from BPOM carried out a comprehensive review of the facilities, including laboratory operations, documentation systems, drug storage conditions, temperature monitoring, operational SOPs, and the conduct of both clinical and bioanalytical phases of the studies.

The ...

PT Biometrik Riset Indonesia Wins Ministry of Health Tender for Bioequivalence Testing Services in 2025

Writer: Pandu Saputra; Editor: Rizky Puspita Dewi

Jakarta, August 22, 2025 – PT Biometrik Riset Indonesia is proud to announce its success in winning the tender from the Ministry of Health of the Republic of Indonesia (Kemenkes RI) for providing bioequivalence (BE) testing services and facilitation of the change from imported to domestic raw materials for the drugs sitagliptin, imatinib, and rivaroxaban for the 2025 fiscal year.

This renewed trust from the Ministry of Health reinforces PT ...

Writer : Andi Darmawan

On September 10, 2025, PT Biometrik welcomed a sponsor audit at its laboratory facilities. One of the sponsors conducting the audit was PT Tropica Mas Pharmaceuticals, as part of their evaluation to ensure that the laboratory meets all regulatory requirements and international standards before being entrusted with conducting bioequivalence studies.

The audit was carried out over a full day and covered a wide range of critical aspects, including:

• Quality Management System, reviewing standard operating procedures (SOPs), documentation, and quality control workflows implem...